In a report released today, Michael Petusky from Barrington maintained a Buy rating on Henry Schein (HSIC – Research Report), with a price target of $86.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michael Petusky has given his Buy rating due to a combination of factors, including Henry Schein’s solid financial performance and effective management strategies. The company reported a strong non-GAAP EPS of $1.15 for the quarter, surpassing both the firm’s and consensus estimates, primarily due to effective expense management.
Furthermore, Henry Schein has maintained its fiscal year 2025 financial guidance, projecting a moderate increase in revenue and adjusted EBITDA growth in the mid-single digits. Despite a slight reduction in the price target from $90 to $86, the overall outlook remains positive, with a projected upside of 29% to the new price target. These factors contribute to the confidence in Henry Schein’s ability to manage challenges such as tariff impacts, supporting the Buy recommendation.
According to TipRanks, Petusky is a 3-star analyst with an average return of 2.0% and a 45.13% success rate. Petusky covers the Healthcare sector, focusing on stocks such as SurModics, Option Care Health, and Merit Medical Systems.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $85.00 price target.